Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention.
Random periareolar fine-needle aspiration (RPFNA) is a research procedure designed to (a) evaluate short-term breast cancer risk in women at high risk for developing breast cancer, and (b) track response to chemoprevention. Of import, cellular atypia in breast RPFNA is prospectively associated with a 5.6-fold increase in breast cancer risk in women at high risk. Among 99 women attending a clinic for high-risk breast cancer, we explored the effects of RPFNA cytology results on decision making pertaining to the use of tamoxifen for breast cancer chemoprevention. No patient with nonproliferative or hyperplastic cytology subsequently elected to take tamoxifen. Only 7% of subjects with borderline atypia elected to take tamoxifen. In contrast, 50% with atypia elected to take tamoxifen. These results suggest that the provision of a biomarker of short-term risk can affect the motivation to take tamoxifen for chemoprevention. This conclusion is informative given that tamoxifen, due to its side effects, is often underused by women at high risk of developing breast cancer. Further research is needed to determine the mechanisms through which RPFNA results affect the decision to use tamoxifen, or any other breast cancer chemopreventive agent.
Goldenberg
Vanessa K
VK
Duke University Medical Center, Durham, North Carolina, USA.
Seewaldt
Victoria L
VL
Scott
Victoria
V
Bean
Gregory R
GR
Broadwater
Gloria
G
Fabian
Carol
C
Kimler
Bruce
B
Zalles
Carola
C
Lipkus
Isaac M
IM
D000328:Adult; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D044963:Biopsy, Fine-Needle / Q000379:methods; D001940:Breast / Q000166:cytology / Q000473:pathology*; D001943:Breast Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000517:prevention & control*; D018270:Carcinoma, Ductal, Breast / Q000175:diagnosis / Q000473:pathology / Q000517:prevention & control*; D018275:Carcinoma, Lobular / Q000175:diagnosis / Q000473:pathology / Q000517:prevention & control*; D015331:Cohort Studies; D003657:Decision Making; D005260:Female; D006801:Humans; D008875:Middle Aged; D009558:Nipples; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D013629:Tamoxifen / Q000627:therapeutic use*
D016588:Anticarcinogenic Agents; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen